- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01957059
A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase I/II, Open-label, Dose Escalating With 48 Week Treatment Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of BMN053 (Previously Known as PRO053) in Subjects With Duchenne Muscular Dystrophy.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium, 3000
- UZ Leuven, Campus Gasthuisberg
-
-
-
-
-
Paris, France, 75651
- Institut de Myologie
-
-
-
-
-
Rome, Italy, 00168
- Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Leiden, Netherlands, 2333ZA
- Leids Universitair Medisch Centrum
-
-
-
-
-
London, United Kingdom, WC1N 3JH
- Great Ormond Street Hospital for Children
-
Newcastle, United Kingdom, NE1 3BZ
- Institute of Genetic Medicine International Centre for Life
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Duchenne muscular dystrophy resulting from a mutation correctable by treatment with BMN053 confirmed by a state-of-the-art DNA diagnostic technique covering all DMD gene exons, including but not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or HRMCA (High-Resolution Melting Curve Analysis).
- Ambulant boys aged at least 5 years on the day of first dosing able to walk for at least 300 metres in the 6 minute walking distance (6MWD) test. In addition, results of the 6MWD test must be within ±30 metres of each other at 2 of 3 pre-treatment visits (screen 1, 2 and baseline) prior to first BMN053 administration.
- Adequate quality for biopsy (confirmed with MRI) of the lateral head of the gastrocnemius muscle. Only under exceptional circumstances will an alternative muscle (preferably brachii) be considered for biopsy and only following discussion between the Principal Investigator and the BioMarin Medical Monitor.
- Life expectancy of at least 3 years after inclusion in the study.
- Glucocorticosteroid use which is stable for at least 3 months prior to first BMN053 administration. Subjects must have been receiving glucocorticosteroids for at least 6 months prior to the first BMN053 administration.
- Willing and able to adhere to the study visit schedule and other protocol requirements.
- Written informed consent signed (by parent(s)/legal guardian and/or the subject, according to the local regulations).
- In France, a subject will be eligible for inclusion in this study only if either affiliated to, or a beneficiary of, a social security category.
- Anticipated adequate vein access for intravenous (IV) infusion.
Exclusion Criteria:
- Current or history of liver disease or impairment.
- Current or history of renal disease or impairment.
- At least two aPTT above upper limit of normal (ULN) within the last month prior to first dose of BMN053.
- Screening platelet count below the lower limit of normal (LLN).
- Acute illness within 4 weeks prior to first dose of BMN053 which may interfere with the study assessments.
- Severe mental retardation and/or behavioural problems which, in the opinion of the Investigator, prohibit participation in this study.
- Severe cardiomyopathy which, in the opinion of the Investigator prohibits participation in this study. If a subject has a left ventricular ejection fraction <45% at screening, the Investigator should discuss inclusion of the subject with the Medical Monitor.
- Expected need for daytime mechanical ventilation within the next year.
- Use of anticoagulants, antithrombotics or antiplatelet agents.
- Use of idebenone or other forms of coenzyme Q10 within 1 month prior to the start of the screening for the study.
- Use of nutritional or herbal supplements which, in the opinion of the Investigator, may influence muscle performance within 1 month prior to first dose of BMN053.
- Use of any other investigational product or participation in another trial with an investigational product, within 6 months prior to the start of the screening for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation phase
In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject).
In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week).
The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2).
The actual doses may be amended or repeated based on emerging data from previous doses.
|
All doses of BMN053 have been administered as subcutaneous injections.
|
Experimental: Regimen selection
After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks.
3 more treatment-naïve subjects will be entered into this Group.
These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC.
At the time of this amendment (4) this part of the study has been completed.
Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing).
Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
|
All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows: • 3 mg/kg All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows: • 4-6 mg/kg |
Experimental: 48-week Treatment Phase
Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis. Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level). After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate). |
All doses of PRO053 will be administered as IV infusions.
The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
|
Experimental: Dosing extension
All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053.
Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored.
The dose extension phase will provide BMN 053 treatment for 48 weeks.
|
All doses of PRO053 will be administered as IV infusions.
The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in 6 minute walk test
Time Frame: after 48 weeks of treatment phase
|
after 48 weeks of treatment phase
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Muscle strength
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Muscle function
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Pulmonary function
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Functional outcomes questionnaire
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Adverse Events
Time Frame: after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
Safety Laboratory
Time Frame: after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
Cardiac function
Time Frame: after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
Pharmacokinetic parameters at different dose levels
Time Frame: after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
after single intravenous and subcutaneous doses, and after 48 weeks of treatment phase
|
Presence of (BMD-like) dystrophin expression in muscle biopsy
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Production of exon skip 53 mRNA in muscle biopsy
Time Frame: after 48 weeks treatment phase
|
after 48 weeks treatment phase
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: V. Straub, Prof., Institute of Genetic Medicine, Newcastle University, UK
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO053-CLIN-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
-
Ondokuz Mayıs UniversityCompletedDuchenne Muscular Dystrophy (DMD)Turkey
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Parent Project, ItalyCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
GenethonInstitute of MyologyCompletedDuchenne Muscular Dystrophy (DMD)France
-
Ann & Robert H Lurie Children's Hospital of ChicagoChildren's National Research InstituteWithdrawnDuchenne Muscular Dystrophy (DMD)United States
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
Clinical Trials on Regimen Selection Phase Group 1 (COMPLETED)
-
University of MinnesotaArizona State UniversityCompleted
-
University of MichiganReuben Phoenix Schostak Fontan Wellness Project FundRecruitingFrailty | Fontan Physiology | Single Ventricle Heart DiseaseUnited States
-
Actimed Therapeutics LtdQuotient SciencesCompleted
-
University of FloridaCompleted
-
Wake Forest University Health SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
-
Zulekha HospitalsCompletedRegional Anesthesia MorbidityEgypt
-
New York Medical CollegeRecruitingHodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingNon Small Cell Lung CancerChina
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); Genzyme, a Sanofi CompanyCompletedAcute Myeloid LeukemiaUnited States, Singapore